Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Delcath Systems, Inc./ 10-K

Annual Report · 10-K

Delcath Systems, Inc.

DCTHNASDAQEQUITYCurrent

Annual Report

Filed Feb 26, 2026Accepted Feb 26, 2026, 9:15 AM ESTCIK 872912Accession 0001628280-26-012019
View company →Permanent SEC source ↗
Share

Company context

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System (HDS) for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

Current securities

DCTHNASDAQ · EQUITY · Current

Recent company filings

  1. S-8 filingAug 14, 2026
  2. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAug 14, 2026
  3. 10-Q filingAug 6, 2026
  4. Results of Operations and Financial ConditionAug 6, 2026
  5. SCHEDULE 13G filingJul 28, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗